Arcutis Biotherapeutics opened lower at $28.24, compared with its previous close of $28.38. In the last trading session, the stock traded between $27.45 and $28.94. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Arcutis Biotherapeutics is now worth
$ 129.65
Giving a profit of
$ 29.65 (29.65%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.84 (-2.97%)
Day High
$28.94
Day Low
$27.45
Day Open
$28.24
Prev Close
$28.38
Volume
13,76,956
1W Return
-19.55%
1M Return
5.00%
3M Return
5.04%
6M Return
29.65%
1Y Return
14.59%
Fundamentals
Market Cap ($ Mn)
3,482
PE Ratio
108.09
PB Ratio
13.54
PEG Ratio
-
ROE
-10.26%
ROCE
-4.38%
EPS (TTM)
$0.07
Investment Returns
1 Week
-19.55%
1 Month
5.00%
3 Months
5.04%
6 Months
29.65%
9 Months
3.56%
Financials
Quarterly
All values in $ Mn
65.8
Mar 25
81.5
Jun 25
99.2
Sep 25
129.5
Dec 25
129.9
Jun 26
143.9
Sep 26
Updates
7Nov
Arcutis Biotherapeutics grants RSUs and options to six new hires
Granted 58,500 RSUs and options for 17,000 shares to six new employees. Awards approved under the 2022 Inducement Plan with a November 2, 2026 grant date. Options have a $31.26 exercise price and a ten-year term. Compliance with Nasdaq Listing Rule 5635(c)(4) for inducement grants.
6 days ago
6Nov
TD Cowen maintains Buy on Arcutis Biotherapeutics, lifts target to $40
TD Cowen maintains a Buy rating on Arcutis Biotherapeutics. Price target raised from $35 to $40 by analyst Tyler Van Buren. The new target represents a $5 increase over the prior level.
Arcutis Biotherapeutics entered an amended sales agreement with TD Cowen. The company may sell up to $200,000,000 in aggregate common stock. Sales will occur via at-the-market offering on Nasdaq Global Select Market. Last reported sale price was $32.00 per share on November 3, 2026.
8 days ago
5Nov
Arcutis Biotherapeutics Q3FY26 Results: Revenue up 45% YoY to $143.9M
Net product revenue rose 45% YoY to $143.9 million, driven by strong ZORYVE demand exceeding 300,000 prescriptions. Full-year 2026 revenue guidance raised to $535–545 million, up from previous $525–540 million range. SG&A expenses surged 60% YoY due to Simone Biles marketing campaign and sales force expansion, outpacing revenue growth. Company maintains positive operating cash flow of $18.9 million despite heavy strategic investments.
8 days ago
19Oct
Guggenheim maintains Buy on Arcutis Biotherapeutics, raises target to $44
Guggenheim maintains Buy rating on Arcutis Biotherapeutics. Price target raised from $38 to $44. Analyst Seamus Fernandez issued the update.
24 days ago
15Oct
Cantor Fitzgerald initiates Arcutis Biotherapeutics with Overweight rating
Cantor Fitzgerald initiated coverage on Arcutis Biotherapeutics. Analyst Steve Seedhouse assigned an Overweight rating. Price target set at $48 per share.
